dr. M. (Marcel) Hoppentocht

Post-doctoral Researcher

No picture available
m.hoppentocht rug.nl


Research interests

Main topic of my research is dry powder inhalation of antibiotics, especially in tuberculosis and bronchiectasis therapy. Currently, these antibiotics are administered via nebulisation or via the parenteral route. These routes have numerous disadvantages which are at the cost of good patient compliance. Nebulisation is very time-consuming, electricity or pressurized air is needed and nebulisers are not very portable. Major disadvantages of parenteral dosage forms are the needle and the need for a ‘cold chain’.
The dry powder inhalers (DPIs) I use in the studies are the Twincer and derivatives thereof. The Twincer was developed within our department and is designed for extremely high doses which are necessary for pulmonary treatment of bacterial infections. The dispersion principle of the Twincer is based on air classifier technology, which is currently optimized for the dispersion of colistimethate sodium. It is a very effective inhaler for this drug and it could therefore be suitable to use for other antibiotics too. My job is to investigate the physical and physico-chemical properties of these antibiotics that (are likely to) influence or control the interparticulate forces in the powder and the dispersion process in the DPI. Based on the knowledge from the drug characterization studies it may be possible to group drugs into classes that require specific classifier designs or alternative dispersion principles for good dispersion. It may also result in exploring the applicability of different particle preparation and/or particle engineering techniques to modify the drug properties in a way that improves dispersion and retention in the DPI. The main focus will lie on a new compound called BAL30072.
After optimization, BAL30072 and various other antibiotics are tested in clinical studies. In this respect, a fruitful collaboration exists with the Department of Pulmonary Diseases and Tuberculosis of the University Medical Center Groningen.

  1. Inhalatie van droog poeder veelbelovend bij longinfectie: Pulmonale toediening antibiotica: snelle werking en minder bijwerkingen

    Hoppentocht, M., 29-Apr-2016, In : Pharmaceutisch Weekblad. 151, 17, p. 10-11 2 p.

    Research output: Contribution to journalArticleProfessional

  2. Dry powder inhalation: past, present and future

    de Boer, A., Hagedoorn, P., Hoppentocht, M., Buttini, F., Grasmeijer, F. & Frijlink, H. W., Apr-2017, In : Expert Opinion on Drug Delivery. 14, 4, p. 499-512 14 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (15) »

ID: 271140